Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipovirtide in HIV-infected Patients Not Receiving Antiretroviral Therapy
NCT05349968Phase 1Completed
- Sponsor
- Shanxi Kangbao Biological Products
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1 trial of lipovirtide in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Shanxi Kangbao Biological Products. Primary endpoints: Changes from baseline in respiration rate, Changes from baseline in blood pressure and 3 more. Started Jun 2022; status: completed.
02
Drugs
lipovirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05349968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349968.